Bone, as the largest tissue organ of the human body, bears the important duties of life activities, but it is most likely to cause defects due to trauma, infection, deformity and other reasons. According to statistics, more than 3.5 million patients need bone transplants each year in China. Bone graft material has become the most demanded graft after blood. Osteoprosthesis in bone transplantation is the key technology of almost all orthopedic surgery, and it is also an important factor that directly affects the efficacy. For patients with large bone defects, the improvement of bone repair technology may allow patients to avoid multiple operations, even the fate of amputation.
At present, autogenous bone transplantation is still the gold standard for clinical bone transplantation. Autogenous bone provides the best osteoinductive, osteoconductive and osteogenic activity, but the average incidence of complications is 29.2%, which is often limited by age Elderly people are not suitable to take autogenous bones due to osteoporosis and adolescents because the bones are not yet fully mature, and it is difficult to meet the needs of large segment bone repair. None of the current bone repair materials can achieve the osteogenic repair effect of autologous bone. One of the main reasons is the lack of bioactive ingredients. Therefore, how to improve the osteogenic activity of bone repair materials has become a focus?
Bone marrow contains a large number of components that are beneficial to osteogenesis. In addition to stromal cells, hematopoietic stem cells (HBSC), mesenchymal stem cells (MSCs), and growth factors are also present. Enriching the effective components in bone marrow into bone repair materials is the key to giving them biological activity, and it is also the key to improve the osteogenesis effect of bone repair materials. As a result, the negative pressure enricher for bone growth was born, which solved the key technical problem of lack of biological activity of bone materials.
The bone marrow concentrator is a new medical device product developed by Chongqing Forworth Medical Devices Co., Ltd. This product is the first of its kind in China. It has obtained a medical device registration certificate in April 2013. The first products have been put on the market and will provide a new tissue engineering bone construction solution for patients with bone transplantation, especially those who are not suitable for autologous bone transplantation. , Reduce the risk of surgery and improve the quality of life and quality of life of patients.
Chongqing FWS Medical Device Co., Ltd. takes "loyalty, honesty, solidarity, cooperation and professional focus" as its core values. Based on the research and development and production of orthopedic medical device products, it provides customers with the best products through innovative design and excellence To achieve the goal of improving human health. The bone marrow concentrator produced by Chongqing FWS Medical Devices Co., Ltd. has been listed on the market. We hope that companies and individuals with common ideals and goals will contact us so that we can contribute to the human health cause and make people's lives better. Healthier, happier and happier, fulfilling our "Chinese Dream".
